Breast Cancer
FDA expands Verzenio approval for high-risk breast cancer
The FDA expanded the approval of abemaciclib, combined with endocrine therapy, as adjuvant treatment for adults with hormone receptor-positive, HER2-negative, node-positive early breast cancer.
Surgery before 8 weeks not associated with worse survival in breast cancer
Women who had surgery up to 8 weeks after breast cancer diagnosis did not have worse overall survival than those with earlier times to surgery, according to a case series with more than 373,000 women published in JAMA Surgery.
Chemotherapy-induced peripheral neuropathy common after taxane therapy for breast cancer
Two-thirds of patients with breast cancer treated with taxane-based therapy experienced clinically meaningful chemotherapy-induced peripheral neuropathy symptoms during the first year of treatment, according to prospective study results.
Social factors, tumor biology equally linked to racial disparity in breast cancer survival
Black women with ER-positive, early-stage breast cancer appeared at significantly higher risk for death than their white counterparts, according to study results published in JAMA Oncology.
Healio | HemOnc Today announces new physician leadership
Optimizing CV health behaviors may lower risk for CVD and cancer
Improvement in the American Heart Association’s Life’s Simple 7 CV health score was associated with lower risk for cancer and CVD during nearly 25 years of follow-up, researchers reported.
All-cause, CVD mortality highest in Black patients among those with cancer
Researchers observed significant racial disparities in all-cause and CVD mortality among adults with cancer, with wider gaps found among patients younger than 55 years, according to a study published in JACC: CardioOncology.
Omission of radiation ‘is an option’ for some older women with early breast cancer
Omission of whole-breast irradiation did not appear to have a negative impact on survival or risk for distant metastases among older women with early-stage hormone receptor-positive breast cancer, according to phase 3 study results.
Oncolytic virus therapy may boost antitumor response in triple-negative breast cancer
The oncolytic virus talimogene laherparepvec combined with neoadjuvant chemotherapy appeared safe and effective for women with early-stage triple-negative breast cancer, according to phase 2 study results published in Nature Medicine.
Researchers explore connections between cancer and genetic ancestry
Researchers at Cold Spring Harbor Laboratory have developed software that correctly deduces continental ancestry from tumor DNA and RNA.